Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.53+0.13 (+9.29%)
Close on Nov 13, 2026Market cap $11.00MP/E 1.1Yield –
Chemomab Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Chemomab Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2023 was $23.23M, up 143.7% year over year. For fiscal 2025 it was $5.83M, down 48.5% from the year before. The highest annual figure on record is $18.38M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.83M | -48.5% |
| FY2024 | Dec 31, 2024 | $11.33M | -38.4% |
| FY2023 | Dec 31, 2023 | $18.38M | +8.3% |
| FY2022 | Dec 31, 2022 | $16.98M | +168.0% |
| FY2021 | Dec 31, 2021 | $6.33M | +35.2% |
| FY2020 | Dec 31, 2020 | $4.68M | -64.8% |
| FY2019 | Dec 31, 2019 | $13.30M | +77.0% |
| FY2018 | Dec 31, 2018 | $7.51M | +20.6% |
| FY2017 | Dec 31, 2017 | $6.23M | +161.3% |
| FY2016 | Dec 31, 2016 | $2.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.14M | -83.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.29M | -78.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.93M | -46.0% |
| Q2 FY2023 | Jun 30, 2023 | $5.02M | +72.3% |
| Q1 FY2023 | Mar 31, 2023 | $6.89M | +150.9% |
| Q4 FY2022 | Dec 31, 2022 | $5.90M | +147.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.42M | +264.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.91M | +123.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.75M | +137.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.38M | +90.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.49M | +44.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.31M | +54.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.16M | -25.5% |
| Q4 FY2020 | Dec 31, 2020 | $1.25M | +22.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.03M | -81.5% |
| Q2 FY2020 | Jun 30, 2020 | $847.00K | -67.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.55M | -62.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.03M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.57M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.58M | – |
| Q1 FY2019 | Mar 31, 2019 | $4.14M | – |
See a number that looks wrong?